Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry
Article first published online: 17 JAN 2012
1999 Pharmacotherapy Publications Inc.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 19, Issue 6, pages 675–689, June 1999
How to Cite
Tan, J. Y. and Levin, G. M. (1999), Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry. Pharmacotherapy, 19: 675–689. doi: 10.1592/phco.19.9.675.31538
- Issue published online: 17 JAN 2012
- Article first published online: 17 JAN 2012
During the past decade, treatment options for depression have increased with the introduction of new agents. Older agents, such as tricyclic antidepressants and monoamine oxidase inhibitors, increase noradrenergic and serotonergic neurotransmission. Attempts to separate antidepressant effects from adverse effects led to the development of selective serotonin reuptake inhibitors (SSRIs). Citalopram is the newest SSRI to be marketed in the United States. Of all SSRIs on the market, it is the most selective for serotonin reuptake pump. Its efficacy in treating depression was evident in both placebo-controlled and comparator trials. In addition, citalopram was studied in the treatment of other psychiatric disorders. The agent has less inhibition of cytochrome P450 enzymes than other SSRIs, possibly giving it a lower potential for drug interactions.